Mirati Therapeutics Interest Expense 2011-2026 | MRTX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Mirati Therapeutics

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
19.2 M	-5.3 M	11.4 M	8.85 M	4.21 M	1.1 M	661 K	170 K	-77 K	-1.08 M	251 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
19.2 M	-5.3 M	3.58 M

Quarterly Interest Expense Mirati Therapeutics

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10.2 M	10.4 M	9.24 M	-	13.1 M	760 K	-4.17 M	-	2.74 M	-2.24 M	-3.26 M	-	1.34 M	2 M	2.83 M	-	2.79 M	1.95 M	1.85 M	-	1.37 M	801 K	637 K	-	251 K	277 K	244 K	-	160 K	166 K	204 K	-	-17 K	70 K	46 K	-	24 K	73 K	-202 K	-	462 K	-694 K	-570 K	-	34 K	70 K	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
13.1 M	-4.17 M	1.51 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
BioNTech SE BNTX	14.2 M	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akari Therapeutics, Plc AKTX	100 K	$ 3.54	-20.81 %	$ 238 B	Britain
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	5.2 M	$ 330.34	3.6 %	$ 43.3 B	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
AbbVie ABBV	2.89 B	$ 206.69	-1.01 %	$ 366 B	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.09	-0.97 %	$ 437 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.39	-3.69 %	$ 1.01 B	Canada
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 8.22	2.37 %	$ 225 M	Israel
Ardelyx ARDX	4.5 M	$ 5.97	0.51 %	$ 1.44 B	USA
Cerevel Therapeutics Holdings CERE	10.6 M	-	-	$ 7.29 B	USA
Akebia Therapeutics AKBA	58 K	$ 1.32	-4.35 %	$ 339 M	USA